Post by
colourama on Mar 27, 2024 11:07am
Thoughts on quarter and outlook?
Seems like the quarter was pretty much as expected. They are guiding for about $20mill CAD in adjusted EBITDA in the next year based on the given numbers. If we put a 15x multiple on that, that gives a share price of about $1.90-$2. Is it unreasonable to think we should be in that price range?
Comment by
dogatcat on Apr 01, 2024 11:58am
I agree. If they are able to deliver on 10% to 15% organic growth for the full year, we should be a $2 stock. I like the results. Sales keep growing. As more and more health plans continue to add IVF products, the sales numbers should keep going up.